Key Takeaways
- • Vermont Governor Phil Scott signed H.583 into law on June 15, 2026, establishing the first statutory framework restricting private equity and hedge fund control over clinical decision-making in health care, effective March 1, 2027.
- • The law permits PE and hedge fund ownership of health care facilities but prohibits investor influence over specified clinical and operational functions that may affect patient care, creating a meaningful distinction between ownership and control rights.
- • H.583 establishes a new reporting regime requiring disclosure of ownership, investment, and control relationships involving Vermont health care facilities and management services organizations (MSOs), enhancing regulatory transparency.
- • The restriction focuses on clinical decision-making authority rather than ownership restrictions, leaving room for alternative structures such as physician-controlled MSOs (PC-MSOs) that may provide compliance pathways for investors.
- • Vermont joins a growing number of states—including Washington, New Mexico, and Maine—introducing legislation to limit corporate practice of medicine and restrict financial investors' interference in provider-patient relationships.
Summary
Vermont has enacted the most comprehensive state-level restrictions on private equity and hedge fund involvement in health care decision-making. On June 15, 2026, Governor Phil Scott signed H.583 into law, creating Vermont's first statutory framework specifically addressing PE firm and hedge fund influence over clinical operations in the health care sector. The law becomes effective March 1, 2027, providing stakeholders with a nine-month compliance window.
A critical distinction in H.583 is that it does not prohibit PE or hedge fund ownership of health care facilities outright. Instead, the law focuses on restricting investor control and influence over clinical decision-making and specified operational functions that may affect patient care. This approach creates a bifurcated regulatory model: investors may own health care entities, but licensees must retain decision-making authority over key clinically related business matters. The law accordingly restricts what PE or corporate owners can control, even if they retain equity ownership positions.
The legislation establishes a new reporting and disclosure regime requiring transparency around ownership, investment, and control relationships involving Vermont health care facilities and MSOs. This enhanced regulatory visibility addresses concerns about obscured corporate structures that PE funds commonly use and allows state regulators to monitor investor influence more effectively.
For PE sponsors and hedge fund managers, the law creates strategic planning considerations. While the statute does not technically restrict ownership, practitioners are examining whether alternative structures—such as physician-controlled MSO arrangements—may provide clearer compliance pathways. Ropes & Gray advisors recommend working with counsel to evaluate PC-MSO strategies and other structural approaches within Vermont's new regulatory framework.
H.583 reflects a broader national trend. Lawmakers in Washington, New Mexico, and Maine have recently introduced similar legislation banning or limiting corporate practice of medicine, signaling that state-level restrictions on financial investor interference in provider-patient relationships are becoming standard practice across multiple jurisdictions.
A critical distinction in H.583 is that it does not prohibit PE or hedge fund ownership of health care facilities outright. Instead, the law focuses on restricting investor control and influence over clinical decision-making and specified operational functions that may affect patient care. This approach creates a bifurcated regulatory model: investors may own health care entities, but licensees must retain decision-making authority over key clinically related business matters. The law accordingly restricts what PE or corporate owners can control, even if they retain equity ownership positions.
The legislation establishes a new reporting and disclosure regime requiring transparency around ownership, investment, and control relationships involving Vermont health care facilities and MSOs. This enhanced regulatory visibility addresses concerns about obscured corporate structures that PE funds commonly use and allows state regulators to monitor investor influence more effectively.
For PE sponsors and hedge fund managers, the law creates strategic planning considerations. While the statute does not technically restrict ownership, practitioners are examining whether alternative structures—such as physician-controlled MSO arrangements—may provide clearer compliance pathways. Ropes & Gray advisors recommend working with counsel to evaluate PC-MSO strategies and other structural approaches within Vermont's new regulatory framework.
H.583 reflects a broader national trend. Lawmakers in Washington, New Mexico, and Maine have recently introduced similar legislation banning or limiting corporate practice of medicine, signaling that state-level restrictions on financial investor interference in provider-patient relationships are becoming standard practice across multiple jurisdictions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.